Abstract
Introduction Dengue infection poses significant public health problems in tropical and subtropical regions all over the world. The clinical manifestation of dengue varies from asymptomatic cases to severe dengue manifestation. The detection of clinical cases enables us to measure the incidence of dengue infection, whereas serological surveys give insights into the prevalence of infection. This study aimed to determine the dengue prevalence among healthy adult patients in Bali.
Method Cross-sectional seroprevalence surveys were performed from July 2020 to June 2021 among healthy and adult patients in Denpasar Bali. Blood samples were collected from 539 randomly selected samples from urban sites in Denpasar. IgG antibodies against DENV were detected in serum using a commercial enzyme-linked immunosorbent assay (ELISA) kit.
Results Overall, the positive dengue seroprevalence rate among 539 clinically healthy adult patients was high (85.5%). The subject’s median age was 34.1 (range between 18-86.1) years old. Most participants in the study were younger than 40 years old (61.2%). The gender is dominated by males (54.5%). The study found a significant association of dengue seropositivity among people age more than 40 years old with healthy status (p=0.005 and p<0.001, respectively). Another seroprevalence study reported a lower rate of dengue infection in children in Indonesia (69.4%). The difference may be associated with less probability of Aedes bites among the children. The study reflected the proportion of asymptomatic dengue that needs better assessment with a serological test.
Conclusion The current study highlighted a high prevalence of dengue seropositive with a relatively dominant proportion of asymptomatic cases. The study guides the physicians o to beware of every dengue infection in tropical countries and prevents the spread of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Grant from Ministry of Research and Higher Education Technology Indonesia to SM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Udayana University, Bali, Indonesia (Approval No: 485/UN.14.2/KEP/2020). All study participants were enrolled after providing written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
